360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Suven Life Sciences Ltd

Type: Company

Name: Suven Life Sciences Ltd

Fact Sheet: Fact Sheet for Suven Life Sciences Ltd

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Suven Life Sciences Board recommends Dividend of Rs. 0.30 for 2012-13

The Board of Directors of Suven Life Sciences Ltd at its meeting held on May 14, 2013, has recommended Dividend Re. 30 paisa per equity share of face value of Re. 1/- each (30%) for the financial year ended March 31, 2013 the dividend will be paid on ... [Published Equity Bulls - May 15 2013]

Entities: Suven Life Sciences Ltd, Dividend, Face value, Fiscal Year

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Suven Life Sciences Ltd's PAT Up by 115% for the Year Ended Mar 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!HYDERABAD, INDIA (14 May 2013) SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central ... [Published BioSpace - May 14 2013]

Entities: Suven Life Sciences Ltd, Central Nervous System, Hyderabad (Andhra Pradesh, India)

First reported May 14 2013 - Updated May 14 2013 - 2 reports

Suven Life Sciences net up by 21% in Q4 dividend at 30%

Suvuen Life Sciences, a biopharmceutical company specializing in drug discovery and developmental activities in central nervous system disorders, has notched up net profit growth of 20.9 per cent during the fourth quarter ended March 2013 to Rs.8.63 crore ... [Published PharmaBiz - May 14 2013]

Entities: Suven Life Sciences Ltd, Dividend, Net Profit, Central Nervous System

First reported May 14 2013 - Updated May 14 2013 - 1 reports

SUVEN LIFE SCIENCES LTD. : Suvens PAT up by 115% for the year ended Mar 2013

HYDERABAD, INDIA (14 May' 2013) - SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its audited financial results for the quarter and ... [Published 4 Traders - May 14 2013]

Entities: Suven Life Sciences Ltd, Hyderabad (Andhra Pradesh, India), Drug Discovery, Central Nervous System, Face value

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Suven Life Sciences recommends dividend

, has recommended dividend of 30 paisa per equity share of face value of Re 1 each (30%) for the financial year ended March 31, 2013 the dividend will be paid on and from August 27, 2013, subject to the approval of Members in the ensuing Annual General ... [Published Moneycontrol.com - May 14 2013]

Entities: Suven Life Sciences Ltd, Dividend, Face value

First reported May 10 2013 - Updated May 11 2013 - 1 reports

Seven stocks dominating Friday trade

Source: IRIS (10-MAY-13)Comments | Post CommentShares of 7 companies were buzzing on Friday reacting to their announcement and quarterly earnings. The same are as follows:Shriram Transport Finance Company, India's largest asset financing company, surged ... [Published MyIris - May 10 2013]

Entities: Patent, India, GIC Housing Finance Ltd, Suven Life Sciences Ltd

First reported May 10 2013 - Updated May 10 2013 - 9 reports

Suven Life Sciences Ltd Secures Three Product Patents for Their NCEs in Canada and Eurasia

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!HYDERABAD, INDIA (May 10,2013) Suven Life Sciences Ltd (Suven) announces today that the grant of two product patents from Canada (2672190 and 2703157) and one ... [Published BioSpace - May 10 2013]

Entities: Suven Life Sciences Ltd, Canada, Patent, Hyderabad (Andhra Pradesh, India)

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Suven Life Sciences to consider dividend

, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2013 and to consider and recommend dividend if any, for the financial year 2012-13. ... [Published Moneycontrol.com - May 06 2013]

Entities: Suven Life Sciences Ltd, Dividend, Fiscal Year

First reported Apr 28 2013 - Updated Apr 28 2013 - 1 reports

Andhra Pradesh: From bulk drugs to affordable medicines, vaccines

?In Hyderabad, entrepreneurs are driven by a herd mentality. If there is one successful venture, a dozen will follow. The high number of bulk drug manufacturers in a way is just manifestation of such a trend?. Habil Khorakiwala, Chairman of Wockhardt, ... [Published Hindu Business Line - Apr 28 2013]

Entities: Hyderabad (Andhra Pradesh, India), Vaccine, Drugs, Natco Pharma Limited

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Indian generics grab a strategic foothold in Japan

The recent announcement that Indian generic manufacturer Suven Life Sciences was granted four pharmaceutical patents in China, Mexico and New Zealand, adding to the five patents it holds in Japan, once again shows that Indian generics have steadily been ... [Published Intellectual Asset Management - Apr 25 2013]

Entities: Japan, Suven Life Sciences Ltd, Patent

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

Suven Life Sciences receives four product patents for NCEs

Suven Life Sciences, a biopharmaceutical company, has received four product patents for its new chemical entities (NCEs). ... [Published PBR - News - Apr 19 2013]

Entities: Suven Life Sciences Ltd, Patent, Chemical

First reported Apr 17 2013 - Updated Apr 17 2013 - 5 reports

Suven gets nod for 4 CNS molecules

Biopharmaceutical company, Suven Life Science has fetched product approvals for four of its new chemical entities in China, Mexico and New Zealand. These products are used to treat neuro-degenerative disorders like Alzheimer’s and others.Of these grants, ... [Published Financial Chronicle - Apr 17 2013]

Entities: Molecule, Patent, Huntington's Disease, Alzheimer's Disease

Quotes

...Commenting on the development, Suven CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally." With these new patents, the company now has a total of 12 patents from Canada and 13 patents from Eurasia

Suven Life gets three patent products for CNS molecules [Published Indian Mirror - May 10 2013]

Research and Markets has announced the addition of the "" report to their offering. " provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Huntington's Disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Huntington's Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Huntington's Disease Therapeutics Development - Accera, Inc. - Aegera Therapeutics Inc. - Alnylam Pharmaceuticals Inc - Auspex Pharmaceuticals - BrainStorm Cell Therapeutics Inc. - Ceregene Inc. - Cortex Pharmaceuticals Inc. - GW Pharmaceuticals plc - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Ipsen S A - Isis Pharmaceuticals Inc. - Living Cell Technologies Limited - Neuralstem Inc. - NsGene A/S - Omeros Corporation - Oryzon - Prana Biotechnology Limited - Prosensa Therapeutics B V - Raptor Pharmaceuticals Corp. - SCYNEXIS Inc. - Sangamo BioSciences Inc. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - The Avicena Group Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - Vybion, Inc. - Wellstat Therapeutics Corporation Drug Profiles - Cholesterol Absorption Inhibitor - Cyclophilin Inhibitory Compounds - Drug For Huntington's Disease - Drug For Neuroprotection Program 1 - Drug for Huntington's Disease - Epigallocatechin Gallate - GPCR Antagonist Program - GSK-356278 - Huntington Disease Therapy - Huntington's Disease Therapy - INDUS-815C - Lentivirus-CNTF - Lithium citrate - MTP-131 - Monoclonal Antibodies Targeting Complement System - NNI-370 - NSD-726 - NTCell - NurOwn Stem Cell Therapy - OMS-824 - OXD-4 - PBT-2 - PDE10 Inhibitor - PMX-53 - PRO-289 - Phosphodiesterase Type 5 Inhibitors - Pridopidine - RNAi For Trinucleotide Repeat Diseases - Ubidecarenone - Uridine triacetate For more information visit Research and Markets CONTACT: Research and Markets, Laura Wood, Senior Manager. press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Central Nervous System (http://www.researchandmarkets.com/categories.asp?cat_id=117&campaign_id=hbtsgw)"

Huntington's Disease - Pipeline Review, H1 2013 [Published Individual.com - Apr 17 2013]

More Content

sort by: Date \| Relevance
Suven Life Sciences Board recommends Dividend o... [Published Equity Bulls - May 15 2013]
Suven Life Sciences Ltd's PAT Up by 115% for th... [Published BioSpace - May 14 2013]
Suven Life Sciences net up by 21% in Q4 dividen... [Published PharmaBiz - May 14 2013]
SUVEN LIFE SCIENCES LTD. : Suvens PAT up by 115... [Published 4 Traders - May 14 2013]
Suven Life Sciences recommends dividend [Published Moneycontrol.com - May 14 2013]
Suven Q4 net up 20% at Rs 8.63 crore [Published Business Standard India - May 14 2013]
Suven Life Sciences Ltd Secures Three Product P... [Published BioSpace - May 10 2013]
Suven Life gets three patent products for CNS m... [Published Indian Mirror - May 10 2013]
Suven Life Sciences Ltd. Receives Three New Pat... [Published TopNews New Zealand - May 10 2013]
Seven stocks dominating Friday trade [Published MyIris - May 10 2013]
Suven Life gets 3 more product patents [Published Hindu Business Line - May 10 2013]
Suven Life bags product patents in Canada, Eurasia [Published MyIris - May 10 2013]
Suven Life gets patent for 3 NCE's from Canada ... [Published PharmaBiz - May 10 2013]
Suven Life secures three more patents [Published Business Standard India - May 10 2013]
Suven Life Sciences jumps on securing three pro... [Published Arihant Capital - May 10 2013]
Suven Life secures 3 product patents for their ... [Published India Infoline - May 10 2013]
Suven Life Sciences to consider dividend [Published Moneycontrol.com - May 06 2013]
Andhra Pradesh: From bulk drugs to affordable m... [Published Hindu Business Line - Apr 28 2013]
Indian generics grab a strategic foothold in Japan [Published Intellectual Asset Management - Apr 25 2013]
Schizophrenia - Pipeline Review, H1 2013: New r... [Published Live-PR.com - Apr 20 2013]
Suven Life Sciences receives four product paten... [Published PBR - News - Apr 19 2013]
Suven gets nod for 4 CNS molecules [Published Financial Chronicle - Apr 17 2013]
Suven Life Sciences gets four patents [Published Hindu Business Line - Apr 17 2013]
SUVEN LIFE SCIENCES LTD.: Suven Life Sciences s... [Published 4 Traders - Apr 17 2013]
Huntington's Disease - Pipeline Review, H1 2013 [Published Individual.com - Apr 17 2013]
Suven Life Sciences secures 4 product patents f... [Published HDFC Securities - Apr 17 2013]
Suven Life secures four patents [Published Business Standard India - Apr 17 2013]
Suven Life gets 3 product patents for NCEs in E... [Published PharmaBiz - Dec 31 2012]
Suven Life gets 5 product patents for NCEs in C... [Published PharmaBiz - Dec 13 2012]
R&D spending of 30 pharma companies surge by19.... [Published PharmaBiz - Nov 12 2012]

Blogs

sort by: Date \| Relevance
Suven Life Sciences receives four product paten... [Published PBR - News - Apr 19 2013] Suven Life Sciences, a biopharmaceutical company, has received four product patents for its new chemical entities (NCEs). ...